NTLA Stock Recent News
NTLA LATEST HEADLINES
Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive feedback from regulators, potential to initiate a pivotal phase 3 study using NTLA-2002 for hereditary angioedema in Q3 of 2024. It is expected that the global hereditary angioedema market size is projected to reach $6.53 billion by 2025.
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and Chief Financial Officer Eliana Clark - EVP and CTO Conference Call Participants Kostas Biliouris - BMO Capital Markets Joon Lee - Truist Securities Mani Forooher - Leerink Partners Unidentified Analyst - Guggenheim Partners Dae Gon Ha - Stifel Maury Raycroft - Jefferies Gena Wang - Barclays Salveen Richter - Goldman Sachs Luca Issi - RBC Yanan Zhu - Wells Fargo Securities Greg Harrison - Bank of America Joseph Thome - TD Cowen Liisa Bayko - Evercore ISI Rick Bienkowski - Cantor Fitzgerald Terrence Flynn - Morgan Stanley Unidentified Analyst - Myles Minter Jay Olson - Oppenheimer Unidentified Analyst - Bernstein Silvan Tuerkcan - JMP Securities David Lebowitz - Citigroup Unidentified Analyst - Raymo
The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.
Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overcome.
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.
Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.